MX2022012384A - Compositions and methods for screening mutations in thyroid cancer. - Google Patents

Compositions and methods for screening mutations in thyroid cancer.

Info

Publication number
MX2022012384A
MX2022012384A MX2022012384A MX2022012384A MX2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A
Authority
MX
Mexico
Prior art keywords
methods
thyroid cancer
compositions
screening
patient
Prior art date
Application number
MX2022012384A
Other languages
Spanish (es)
Inventor
Kevin Qu
Joseph J Catanese
Andrew Grupe
Feras Hantash
Frederic M Waldman
Shih-Min Cheng
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2022012384A publication Critical patent/MX2022012384A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

The present technology relates to methods for determining whether a patient having thyroid nodules with indeterminate cytology will benefit from diagnostic surgery, <i>e.g</i>., lobectomy. These methods are based on screening a patient's thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to a specific set of thyroid cancer- related genes. Kits for use in practicing the methods are also provided.
MX2022012384A 2015-12-31 2018-06-29 Compositions and methods for screening mutations in thyroid cancer. MX2022012384A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273783P 2015-12-31 2015-12-31
US201662439572P 2016-12-28 2016-12-28

Publications (1)

Publication Number Publication Date
MX2022012384A true MX2022012384A (en) 2023-01-16

Family

ID=59225391

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008197A MX2018008197A (en) 2015-12-31 2016-12-30 Compositions and methods for screening mutations in thyroid cancer.
MX2022012384A MX2022012384A (en) 2015-12-31 2018-06-29 Compositions and methods for screening mutations in thyroid cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018008197A MX2018008197A (en) 2015-12-31 2016-12-30 Compositions and methods for screening mutations in thyroid cancer.

Country Status (7)

Country Link
US (2) US11053542B2 (en)
EP (2) EP3397766B1 (en)
CN (1) CN108699553B (en)
BR (1) BR112018013430A2 (en)
CA (1) CA3010013A1 (en)
MX (2) MX2018008197A (en)
WO (1) WO2017117523A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937986A (en) * 2017-11-10 2018-04-20 深圳裕策生物科技有限公司 A kind of FFPE DNA build storehouse kit, its purposes and banking process
CN109371139A (en) * 2018-12-29 2019-02-22 杭州迪安医学检验中心有限公司 A kind of primer and its application being used to detect the variation of thyroid cancer pathogenic related gene based on high throughput sequencing technologies
CN109652535A (en) * 2019-01-30 2019-04-19 上海安甲生物科技有限公司 Identify human thyroid tubercle good pernicious kit and its application method and application
US20210010060A1 (en) * 2019-07-02 2021-01-14 Genenius Genetics Highly Multiplexed PCR with Bioinformatically Optimized Primers to Prepare Targeted Libraries for Next-Generation Sequencing
CN110241215B (en) * 2019-07-03 2020-05-19 上海润安医学科技有限公司 Primer and kit for detecting benign and malignant genetic variation of thyroid nodule
IT201900024009A1 (en) * 2019-12-13 2021-06-13 Univ Degli Studi Roma La Sapienza NEW PROCEDURE FOR THE DIAGNOSIS OF A THYROID CANCER AND RELATED KIT
CN110878358B (en) * 2019-12-19 2020-08-25 上海宝藤生物医药科技股份有限公司 Thyroid cancer markers and application thereof
CN112080566B (en) * 2020-08-25 2021-08-17 上海交通大学医学院附属瑞金医院 Thyroid cancer detection product based on high-throughput sequencing method and application
CN111979327A (en) * 2020-09-01 2020-11-24 上海睿璟生物科技有限公司 Detection kit and detection method for human thyroid gland extraction-free oncogene mutation
CN112011615A (en) * 2020-09-01 2020-12-01 上海睿璟生物科技有限公司 Gene fusion kit for human thyroid cancer and detection method
CN114277115A (en) * 2020-09-27 2022-04-05 上海鹍远生物科技股份有限公司 Thyroid nodule benign and malignant related marker and application thereof
CN113176408B (en) * 2021-06-02 2022-10-11 四川大学华西医院 Method for judging thyroid cancer prognosis
CN117286247A (en) * 2022-09-07 2023-12-26 上海医创云康生物科技有限公司 Thyroid gene detection kit

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795762A (en) 1986-08-22 1998-08-18 Roche Molecular Systems, Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
US5466591A (en) 1986-08-22 1995-11-14 Hoffmann-La Roche Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
DE553264T1 (en) 1990-10-05 1994-04-28 Wayne M Barnes THERMOSTABLE DNA POLYMERASE.
US20080312093A1 (en) * 2005-11-04 2008-12-18 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
CA2557134A1 (en) * 2006-08-23 2008-02-23 National Research Council Of Canada Molecular method for diagnosis of colon cancer
EP2407556B1 (en) * 2009-03-13 2015-12-02 Kabushiki Kaisha Yakult Honsha Method for determining sensitivity to irinotecan and use thereof
US8980554B2 (en) * 2010-07-26 2015-03-17 The Johns Hopkins University Genetic make-up modifies cancer outcome
GB201017011D0 (en) * 2010-10-08 2010-11-24 Skova Services Ltd Assay
EP2505664B1 (en) * 2011-03-30 2014-12-03 Universität Leipzig Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB)
US20130142728A1 (en) * 2011-10-27 2013-06-06 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
CN103088433B (en) * 2011-11-02 2014-09-24 深圳华大基因科技服务有限公司 Construction method and application of genome-wide methylation high-throughput sequencing library and
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
US10260103B2 (en) * 2012-11-27 2019-04-16 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
CA2905461C (en) * 2013-03-14 2022-12-06 Quest Diagnostics Investments Incorporated Method for detecting cystic fibrosis
CN105431549A (en) * 2013-03-27 2016-03-23 麦克·明照·邢 TERT promoter mutations in cancer
WO2015024075A1 (en) * 2013-08-23 2015-02-26 Agriculture Victoria Services Pty Ltd Method of nucleic acid fragmentation
EP3044324A1 (en) * 2013-09-13 2016-07-20 Life Technologies Corporation Classification and actionability indices for cancer
WO2015153808A1 (en) * 2014-04-01 2015-10-08 The Johns Hopkins University Tert and braf mutations in human cancer
CN105200134A (en) * 2015-09-18 2015-12-30 杭州泛生子医学检验所有限公司 Method and reagent kit for detecting mutation of human TERT gene promoter
CN108315424B (en) * 2018-04-10 2021-08-06 广东省人民医院(广东省医学科学院) PCR (polymerase chain reaction) specific primer, detection kit and detection method for thyroid nodule benign and malignant related genes

Also Published As

Publication number Publication date
EP4246144A2 (en) 2023-09-20
CN108699553A (en) 2018-10-23
MX2018008197A (en) 2019-02-20
BR112018013430A2 (en) 2018-12-18
EP3397766A1 (en) 2018-11-07
US20210324468A1 (en) 2021-10-21
CA3010013A1 (en) 2017-07-06
US20190112653A1 (en) 2019-04-18
US11053542B2 (en) 2021-07-06
EP3397766A4 (en) 2019-10-02
EP4246144A3 (en) 2023-12-20
CN108699553B (en) 2023-08-04
EP3397766B1 (en) 2023-05-17
WO2017117523A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
MX2022012384A (en) Compositions and methods for screening mutations in thyroid cancer.
MX2023001945A (en) Compositions and methods for screening solid tumors.
WO2016138105A3 (en) Assays to determine dna methylation and dna methylation markers of cancer
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
MX2014000116A (en) Methods and nucleic acids for determining the prognosis of a cancer subject.
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2017008421A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
WO2015071669A3 (en) Materials and methods for diagnosis and prognosis of liver cancer
WO2015153732A3 (en) Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
NZ707035A (en) Gene signatures of inflammatory disorders that relate to the liver
WO2012109157A3 (en) Bioprobes and methods of use thereof
JP2014144959A5 (en)
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
AU2015308620A8 (en) Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells
WO2019094780A3 (en) Non-coding rna for detection of cancer
MX2019007894A (en) Compositions and methods for detecting circulating tumor dna.
CA2863427A1 (en) Use of pdgfr-.alpha. as diagnostic marker for papillary thyroid cancer
MX2016017136A (en) COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2).
GB2556001A (en) Diagnostic kits
WO2015107430A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
GB2538006A (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2017129753A8 (en) Means and methods for staging, typing and treating a cancerous disease